Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

The stock's rise snapped a four-day losing streak.

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

About the company: SurgeGraph Vertex is an AI writing tool with a mission to help users grow their website traffic through ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...

Baird lowered the firm’s price target on Vertex (VERX) to $45 from $62 and keeps an Outperform rating on the shares. The firm updated its model ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...